SCHEMBL3901263

SCHEMBL3901263

CCOc1ccc(-c2ccc(C[C@H](N)C(=O)Oc3ccc(-c4ccc(C[C@H](N)C(=O)O)cc4)c(CC)c3)cc2)c(CC)c1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SRD5A2 P31213 1/20 0.46
ITGB3 P05106 1/20 0.42
ITGA2B P08514 1/20 0.42
FFAR1 O14842 1/20 0.42
FFAR4 Q5NUL3 1/20 0.42
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
TPH1 P17752 5/20 0.41
PTPN1 P18031 2/20 0.41
SLC7A5 Q01650 3/20 0.39
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
PDE1A P54750 1/20 0.38
PDE1B Q01064 1/20 0.38
PDE1C Q14123 1/20 0.38
ALPI P09923 1/20 0.38
PKM P14618 1/20 0.38
PTGS1 P23219 1/20 0.38
XIAP P98170 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1999882 0.93 SRD5A2 (0.51) SRD5A2ITGB3ITGA2BFFAR1FFAR4
SCHEMBL30040624 0.83 TPH1 (0.54) ITGB3ITGA2BPPARGPPARATPH1
SCHEMBL429637 0.83 TPH1 (0.54) ITGB3ITGA2BPPARGPPARATPH1
SCHEMBL2000467 0.83 TPH1 (0.54) ITGB3ITGA2BPPARGPPARATPH1
SCHEMBL2003104 0.82 PPARG (0.53) ITGB3ITGA2BPPARGPPARATPH1
SCHEMBL158881 0.77 ITGB3 (0.64) ITGB3ITGA2BPPARATPH1PTPN1
SCHEMBL158880 0.77 ITGB3 (0.64) ITGB3ITGA2BPPARATPH1PTPN1
SCHEMBL2036599 0.77 ITGB3 (0.64) ITGB3ITGA2BPPARATPH1PTPN1
SCHEMBL31111394 0.77 ITGB3 (0.48) SRD5A2ITGB3ITGA2BPPARGPPARA
SCHEMBL25311021 0.77 SLC7A5 (0.60) TPH1SLC7A5ALPIPKMPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2021354-A2 N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS Brystol-Myers Squibb Company (US) 2009-02-11 EP claimed
WO-2007140284-A2 N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS BRISTOL-MYERS SQUIBB COMPANY (US) 2007-12-06 WO claimed
US-20070021346-A1 N-terminally modified GLP-1 receptor modulators BRISTOL-MYERS SQUIBB COMPANY 2007-01-25 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070021346-A1 N-terminally modified GLP-1 receptor modulators GLP1R, GIPR, IAPP SRD5A2 4555/4885ITGB3 4192/4885ITGA2B 3396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.